Biogen Shares Down 12% After Announcing Results Of Phase 2 Clinical Study Of BAN2401, Developed With Drugmaker Eisai, In Early Alzheimer's Disease Patients, "No Reasonable Conclusions" To Dar From Data According To Baird's Brian Skorney
Benzinga Newsdesk